Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: A phase II study

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

With respect to their association, sequential non-cross-resistant cytostatics could be better tolerated and allow a similar antitumor effect. From January, 1998 to July, 1999, 42 consecutive patients with metastatic breast cancer (MBC) previously treated with anthracyclines as adjuvant- or first-line therapy entered a phase II multicenter study where docetaxel (TXT, 100 mg/m2/3 weeks/4 times) was followed by vinorelbine (VNR, 25 mg/m2/10 days/8 times). Median follow-up is 21 months and 22/42 patients have died. Four patients did not complete therapy due to early death, grade 3-4 gastrointestinal mucosytis (2 patients) and grade 3 neurotoxicity during TXT therapy. Overall response rate was 57%, and 5% of patients had stable disease. There were 38% of therapy failures due to non-evaluability (10%) or progressive disease (28%). Median time to progression and survival are 10.1 and 17.1 months. Sequential TXT-VNB is a suitable strategy for MBC patients previously treated with anthracyclines. It avoids haematologic toxicity and allows a good antitumor effect. Careful monitoring of intestinal mucosytis is required.

Original languageEnglish
Pages (from-to)801-805
Number of pages5
JournalOncology Reports
Volume8
Issue number4
Publication statusPublished - 2001

Fingerprint

docetaxel
Anthracyclines
Breast Neoplasms
Cytostatic Agents
Therapeutics
Multicenter Studies
vinorelbine

Keywords

  • Docetaxel
  • Metastatic breast cancer
  • Sequential chemotherapy
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{52cdb51c62474c19861fd363343779ee,
title = "Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: A phase II study",
abstract = "With respect to their association, sequential non-cross-resistant cytostatics could be better tolerated and allow a similar antitumor effect. From January, 1998 to July, 1999, 42 consecutive patients with metastatic breast cancer (MBC) previously treated with anthracyclines as adjuvant- or first-line therapy entered a phase II multicenter study where docetaxel (TXT, 100 mg/m2/3 weeks/4 times) was followed by vinorelbine (VNR, 25 mg/m2/10 days/8 times). Median follow-up is 21 months and 22/42 patients have died. Four patients did not complete therapy due to early death, grade 3-4 gastrointestinal mucosytis (2 patients) and grade 3 neurotoxicity during TXT therapy. Overall response rate was 57{\%}, and 5{\%} of patients had stable disease. There were 38{\%} of therapy failures due to non-evaluability (10{\%}) or progressive disease (28{\%}). Median time to progression and survival are 10.1 and 17.1 months. Sequential TXT-VNB is a suitable strategy for MBC patients previously treated with anthracyclines. It avoids haematologic toxicity and allows a good antitumor effect. Careful monitoring of intestinal mucosytis is required.",
keywords = "Docetaxel, Metastatic breast cancer, Sequential chemotherapy, Vinorelbine",
author = "S. Brugnatelli",
year = "2001",
language = "English",
volume = "8",
pages = "801--805",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines

T2 - A phase II study

AU - Brugnatelli, S.

PY - 2001

Y1 - 2001

N2 - With respect to their association, sequential non-cross-resistant cytostatics could be better tolerated and allow a similar antitumor effect. From January, 1998 to July, 1999, 42 consecutive patients with metastatic breast cancer (MBC) previously treated with anthracyclines as adjuvant- or first-line therapy entered a phase II multicenter study where docetaxel (TXT, 100 mg/m2/3 weeks/4 times) was followed by vinorelbine (VNR, 25 mg/m2/10 days/8 times). Median follow-up is 21 months and 22/42 patients have died. Four patients did not complete therapy due to early death, grade 3-4 gastrointestinal mucosytis (2 patients) and grade 3 neurotoxicity during TXT therapy. Overall response rate was 57%, and 5% of patients had stable disease. There were 38% of therapy failures due to non-evaluability (10%) or progressive disease (28%). Median time to progression and survival are 10.1 and 17.1 months. Sequential TXT-VNB is a suitable strategy for MBC patients previously treated with anthracyclines. It avoids haematologic toxicity and allows a good antitumor effect. Careful monitoring of intestinal mucosytis is required.

AB - With respect to their association, sequential non-cross-resistant cytostatics could be better tolerated and allow a similar antitumor effect. From January, 1998 to July, 1999, 42 consecutive patients with metastatic breast cancer (MBC) previously treated with anthracyclines as adjuvant- or first-line therapy entered a phase II multicenter study where docetaxel (TXT, 100 mg/m2/3 weeks/4 times) was followed by vinorelbine (VNR, 25 mg/m2/10 days/8 times). Median follow-up is 21 months and 22/42 patients have died. Four patients did not complete therapy due to early death, grade 3-4 gastrointestinal mucosytis (2 patients) and grade 3 neurotoxicity during TXT therapy. Overall response rate was 57%, and 5% of patients had stable disease. There were 38% of therapy failures due to non-evaluability (10%) or progressive disease (28%). Median time to progression and survival are 10.1 and 17.1 months. Sequential TXT-VNB is a suitable strategy for MBC patients previously treated with anthracyclines. It avoids haematologic toxicity and allows a good antitumor effect. Careful monitoring of intestinal mucosytis is required.

KW - Docetaxel

KW - Metastatic breast cancer

KW - Sequential chemotherapy

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0035406029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035406029&partnerID=8YFLogxK

M3 - Article

C2 - 11410787

AN - SCOPUS:0035406029

VL - 8

SP - 801

EP - 805

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -